University of Arkansas
Fayetteville, Arkansas, 72704, United States
NCT Number: NCT03935048
The prevalence of US adults with Metabolic Syndrome (MetS) is over 34%, impacting nearly 35% of all adults and 50% of those aged 60 years or older. MetS is characterized as a combination of underlying risk factors that when, occurring together, increase the risk for chronic diseases such as type 2 diabetes mellitus (T2DM), cardiovascular disease, stroke, and certain types of cancer, resulting in an 1.6-fold increase in mortality. According the American Heart Association, health risks associated with Metabolic Syndrome can be significantly reduced by reducing body weight and eating a diet that is rich in whole grains, fruits, and vegetables. Potatoes (e.g. skin-on white potatoes) are an excellent source of potassium, vitamin C, and vitamin B6 and a good source of magnesium and dietary fiber. In addition, the potato has greater dry matter and protein per unit growing area compared with cereals. Despite this, consumers tend to believe that potatoes are high in calories and in fat compared with other carbohydrate sources such as rice or pasta, an incorrect assumption since a potato has negligible fat and a low energy density similar to legumes. Data from short-term nutrition intervention trials, suggest that potatoes consumed as part of a low-glycemic load meal can play a role in the prevention or treatment of MetS. However, the impact of long-term potato consumption on cardiometabolic risk factors associated with MetS is not known. Therefore, there is a critical need to determine if regular (> 4 times per week) potato consumption can improve cardiometabolic health in individuals with MetS.
This study is active but is not currently recruiting participants.
Notify Me18 year–85 year
All sexes
Interventional
Not applicable
Fayetteville, Arkansas, 72704, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
All dietary treatments will be designed to be isoenergetic within individual participants. Energy content of the diets will be individualized to ensure weight maintenance throughout the dietary intervention period using the Harris Benedict equation x 1.35. Glycemic load for the treatment groups will be calculated using the following equation:
Glycemic Load = Glycemic Index x Grams of carbohydrates/100. Potatoes, processed potato products, and control carbohydrate foods will be provided.
Time frame: Change from baseline at 16 weeks
Total Cholesterol, LDL-Cholesterol, HDL-Cholesterol, Free Fatty Acids, Triglycerides
Time frame: Change from baseline at 16 weeks
Plasma glucose levels
Time frame: Change from baseline at 16 weeks
Waist circumference in centimeters
Time frame: Change of time of study (16 weeks)
Monthly food records will be recorded to determine changes in diet intake
Time frame: Change from baseline at 16 weeks
Mood will be measured using the Profile of Mood States questionnaire
Time frame: Change from baseline at 16 weeks
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index
Time frame: Change from baseline at 16 weeks
Sleep duration will be assessed using an Actigraph sleep monitor
Time frame: Change from baseline at 16 weeks
Orexin (also known as hypocretin)
Time frame: Change from baseline at 16 weeks
Anorexigenic appetite hormone - PYY (peptide tyrosine tyrosine)
University of Arkansas, Fayetteville
Other
The Effect of a Higher Protein, Lower Glycemic Load Diet Containing Potato or Potato-based Products on Metabolic Health in Adults With Metabolic Syndrome
Acronym: MAPS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07696247
Diabetes Mellitus, Diabetes Mellitus, Type 2
Querétaro City, Querétaro, Mexico
View Trial DetailsNCT06186843
Behavior, Behavior, Animal
Washington D.C., District of Columbia, United States
View Trial DetailsNCT07406191
Body Weight, Cardiovascular Diseases
Erlangen, Germany
View Trial DetailsNCT04974554
Body Weight, Glucose Metabolism Disorders
Charleston, South Carolina, United States
View Trial Details